STOCK TITAN

Immix Biopharma Inc - IMMX STOCK NEWS

Welcome to our dedicated news page for Immix Biopharma (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immix Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immix Biopharma's position in the market.

Rhea-AI Summary
Immix Biopharma, Inc. announced positive interim results from the Phase 1b/2a IMMINENT-01 study of IMX-110 in combination with BeiGene's anti-PD-1 antibody tislelizumab. 75% of patients experienced tumor shrinkage, while 25% had tumor control. The colorectal cancer market is estimated to reach $31 billion by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.11%
Tags
-
Rhea-AI Summary
Nexcella, Inc., a subsidiary of Immix Biopharma, has completed its initial CAR-T NXC-201 engineering batch at its U.S. manufacturing site. This is a significant step towards expanding the Phase 1b/2a NEXICART-1 study of NXC-201 in the U.S. The therapy has shown promising results in AL amyloidosis and multiple myeloma patients, with overall response rates of 100% and 92% respectively. NXC-201 also offers the potential to reduce hospitalization costs and enable dosing in medical centers that currently cannot offer CAR-T cell therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.9%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
management
-
Rhea-AI Summary
Mary Sue Coleman, former Independent Director of Johnson & Johnson, has joined Nexcella, Inc. as a member of the Board of Directors. She brings extensive experience in healthcare and leadership of research-focused institutions. Nexcella is developing an outpatient CAR-T cell therapy for AL amyloidosis and multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none
Immix Biopharma Inc

Nasdaq:IMMX

IMMX Rankings

IMMX Stock Data

72.85M
14.09M
45.91%
8.47%
1.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Los Angeles